MedTrace Logo

Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies

NCT04775888 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-05-14

No results posted yet for this study

Summary

The current treatment of people with haemophilia and other bleeding deficiencies is largely based on clotting factor replacement therapy. The injections can be repeated several times a week according to a personalized schedule. To date, medications are exclusively dispensed in hospital pharmacies to ensure traceability and safety. This retrocession imposes accessibility constraints on patients and on their caregivers, increasing the burden of the disease, particularly in the organization of personal and professional daily life. The PHAREO study aims to investigate patients' perception of accessibility to anti-haemophilia drugs in relation to an evaluation of spatial accessibility in the Auvergne-Rhône-Alpes region (France) in order to consider, if necessary, ways of improving the pathway for patients and their caregivers.

Conditions

  • Health Services Accessibility
  • Blood Coagulation Factor Deficiencies

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône

    lead OTHER

Principal Investigators

  • Laurie Fraticelli, PhD · RESCUe-RESUVal

  • Julie Freyssenge, PhD · RESCUe-RESUVal

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-04-30
Completion
2021-05-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04775888 on ClinicalTrials.gov